Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:2069-2075, doi:10.1016/j.jacc.2005.05.097 (Published online 8 November 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendel, R. C.
Right arrow Articles by Mahmarian, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendel, R. C.
Right arrow Articles by Mahmarian, J. J.

Initial Clinical Experience With Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging

Robert C. Hendel, MD*,1,2,*, Timothy M. Bateman, MD1,2,{dagger}, Manuel D. Cerqueira, MD1,2,{ddagger}, Ami E. Iskandrian, MD1,§, Jeffrey A. Leppo, MD1,||, Brent Blackburn, PhD and John J. Mahmarian, MD1,2,#

* Rush University Medical Center, Chicago, Illinois
{dagger} Cardiovascular Consultants, Kansas City, Missouri
{ddagger} Cleveland Clinic, Cleveland, Ohio
§ University of Alabama at Birmingham, Birmingham, Alabama
|| Berkshire Medical Center, Pittsfield, Massachusetts
CV Therapeutics, Palo Alto, California
# Methodist DeBakey Heart Center, The Methodist Hospital/Baylor College of Medicine, Houston, Texas



View larger version (10K):

[in a new window]
 
Figure 1 The molecular structure of regadenoson (CVT-3146; (1-{9-[(4S, 2R, 3R, 5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2yl]-6aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide).

 


View larger version (16K):

[in a new window]
 
Figure 2 Change in heart rate in beats/min (A) and in systolic blood pressure in mm Hg (B) from baseline after regadenoson administration; values are means with standard errors. Open squares = 400 µg; solid squares = 500 µg.

 


View larger version (141K):

[in a new window]
 
Figure 3 Direct comparison of adenosine and regadenoson images using a dual-isotope protocol (rest: thallium-201, stress: Tc-99m tetrofosmin). These images reveal a large, mild, reversible perfusion defect in the anterior, apical, and lateral walls. Similar findings were noted on the adenosine and regadenoson stress images. Upper panel is the regadenoson study.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement